Abstract | Paraneoplastic glomerulonephritis is a rare complication of malignancy that is frequently mistaken for idiopathic glomerulonephritis. Failure to recognize paraneoplastic glomerulonephritis can subject patients to ineffective and potentially harmful therapy. The pathology of paraneoplastic glomerulonephritis varies between different types of malignancies. This Review discusses the association of glomerulonephritis with both solid tumors and hematological malignancies. The pathogenetic mechanisms of many glomerular lesions seem to relate to altered immune responses in the presence of a malignancy. Studies in the Buffalo/Mna rat model of spontaneous thymoma and nephrotic syndrome indicate that polarization of the immune response toward a T-helper-2 (T H 2) profile has an important role in the development of thymoma-associated glomerular lesions. Furthermore, overexpression of the T H 2 cytokine interleukin 13 in rats induces minimal change disease. Such findings from experimental studies might facilitate the identification of biomarkers that can distinguish paraneoplastic glomerulonephritis from idiopathic and other secondary glomerulonephritides. This Review describes potential pathogenetic mechanisms for paraneoplastic glomerulonephritides associated with different malignancies and highlights the need for a multidisciplinary approach to the management of patients with paraneoplastic glomerulonephritis.
Introduction
Paraneoplastic glomerulonephritides are glomerular lesions that are not directly related to tumor burden, invasion, or metastasis, but rather are induced by products from tumor cells.
1 the first series of paraneoplastic glomerulonephritis was published over 40 years ago by lee et al. 2 since then, solid tumor-associated membranous nephropathy and Hodgkin lymphoma-associated minimal change disease (mCD) have become recognized as 'classic' paraneoplastic glomerulonephritides. other glomerulonephritides, however, including focal segmental glomerulosclerosis (FsGs), membrano proliferative glomerulonephritis, iga nephropathy, and rapidly progressive glomerulonephritis (rPGn), are also associated with malignancy. treatment of paraneoplastic glomerulonephritis is quite different from treatment of idiopathic glomerulonephritis; therefore, recognition of paraneoplastic glomerulonephritis is clinically important. in general, a diagnosis of paraneoplastic glomerulonephritis should be considered if the glomerulonephritis occurs in the presence of malignancy, remits after ablation of the malignancy, and recurs in association with the recurrence of malignancy. 3 However, in reality, the diagnosis of paraneoplastic glomerulonephritis can be diffi cult due to delayed diagnosis of malignancy, presence of other secondary causes of glomerulonephritis, and the rare occurrence of certain paraneoplastic glomerulo nephritides after ablation of a malignancy. 3 this review aims to provide a reference for the diagnosis and treatment of paraneoplastic glomerulo nephritis for the practicing physician and to explore potential pathophysiological mechanisms of paraneoplastic glomerulonephritis with an emphasis on immuno logical mechanisms. the pathogenesis of each type of para neoplastic glomerulonephritis is closely related to the nature of its respective neoplasm. therefore, glomerular lesions associated with solid tumors and hematological malignancies are discussed separately. Glomerular lesions caused by plasma cell dyscrasias such as amyloidosis, light chain deposition disease, and other immuno globulin-related glomerular lesions are induced by mono clonal immunoglobulins or their light or heavy chains. theoretically, these lesions comprise para neoplastic syndromes; however, these disease entities are well established, and are not traditionally considered to be paraneoplastic glomerulonephritides. 1 
Solid tumors
reported cases of paraneoplastic glomerulonephritis associated with common solid tumors based on publications from the past 2 years are shown in Figure 1 . [3] [4] [5] [6] [7] membranous nephropathy is in general the most commonly reported paraneoplastic glomerulonephritis; mCD, membrano proliferative glomerulonephritis, rPGn and iga nephropathy have been reported less frequently. of note, this figure and those subsequent are based on reported cases of paraneoplastic glomerulo nephritis and by no means reflect the epidemiology of paraneoplastic glomerulonephritis.
Membranous nephropathy in a 1999 review, ronco 1 noted that para neoplastic membran ous nephropathy was characterized by a marked male preponderance, age over 50 years, and full-blown nephrotic syndrome. in the majority of cases, ronco noted that the neoplasm and membranous nephropathy manifested themselves within 12 months of each other. these characteristics were confirmed in a 2006 retrospec tive study by lefaucheur et al. 8 to date, this
Key points
The pathogenesis of paraneoplastic glomerulonephritis differs according to ■ whether the disease is associated with a solid tumor, a lymphoid or myeloid malignancy, or a thymoma Polarization of the immune response toward a T-helper-2 profile may lead to the ■ development of minimal change disease or focal segmental glomerulosclerosis in patients with thymoma or Hodgkin lymphoma
Membranoproliferative glomerulonephritis and membranous nephropathy ■ associated with B-cell lymphoma and leukemia are related to the presence of monoclonal immunoglobulin, cryoglobulin, and possibly hepatitis C virus infection
Severe thrombocytosis may induce focal segmental glomerulosclerosis ■ in patients with polycythemia vera, essential thrombocythemia or primary myelofibrosis Autoimmunity in myelodysplastic syndromes may cause a variety of ■ glomerulonephritides
Presence of glomerular inflammatory cells, igG1 and igG2 may aid diagnosis ■ of paraneoplastic membranous nephropathy study represents the largest series of patients with cancerassociated membranous nephropathy. the study is based on a cohort of 240 patients with biopsy-proven membranous nephropathy; the prevalence of cancer in this cohort is 10%. two major risk factors separated para neoplastic membranous nephropathy from idiopathic membranous nephropathy: age over 65 years and smoking >20 packyears. all patients with para neoplastic membranous nephropathy had active cancer. in most patients with paraneoplastic membran ous nephropathy, the diagnosis of cancer and membran ous nephropathy was made within 1 year; however, only half of these patients had symptoms of cancer at the time of membran ous nephropathy diagnosis. the vast majority of tumors in patients with paraneoplastic membran ous nephropathy were carcinomas, which were most frequently localized to the lung (eight patients) and prostate (five patients). interestingly, complete remission of nephrotic syndrome was observed in six of 12 patients whose tumor was in remission, but not in any patient whose tumor was not in remission. these findings support a causal relationship between cancer and membranous nephropathy. the pathology of membranous nephropathy is character ized by subepithelial deposits of immune complex. tumor antigens, including carcinoembryonic antigen, prostate specific antigen, and melanoma antigens, have been reported in conjunction with cancerassociated membranous nephropathy; however, whether these antigens directly cause membranous nephropathy [3] [4] [5] [6] [7] and are presented as number of reported cases of specific types of paraneoplastic glomerulonephritides associated with cancers in each organ. Specific numbers of lung cancer types for membranous nephropathy are: 15 non-small cell lung cancers (NSCLCs), 6 small cell lung cancers (SCLCs), 2 carcinoids, 2 mesotheliomas, 1 lymphoepithelioma. has not been established. 3 one autopsy report that used immunofluorescence labeling described glomerular deposits in 10-27% of kidneys from patients with a malignancy. 9 the incidence of glomerular deposits is even higher if autopsy samples are assessed by electron microscopy. 10 of note, however, the deposits identified by these two studies were found in the mesangial 9 or subendothelial 10 space, which is in contrast to those found in membranous nephropathy. it is possible that tumor antigens per se are not sufficient to cause paraneoplastic membranous nephropathy and enhanced immune reactions triggered by the cancer itself may be required for the development of membranous nephropathy. lefaucheur et al. 8 reported that para neoplastic membran ous nephropathy was characterized by an increased number of inflammatory cells in glomeruli compared with that seen in idiopathic membranous nephropathy. Furthermore, igG1 and igG2 subtypes are markedly more prominent in the kidneys of patients with paraneoplastic membranous nephropathy than in those with idiopathic membranous nephropathy, whereas levels of igG4 are no different.
11
Human igG1 and igG2 are t-helper (t H )-1 cell-related isotypes (driven by interleukin [il]-12 and interferon), whereas igG4 is a t H 2 cell-related isotype (il-4 and il-13-driven).
12 t H 1-predominant responses seem to be strongly associated with proliferative and crescentic forms of glomerulonephritis, which result in severe renal injury, whereas t H 2-type responses are associated with membranous patterns of injury. 13 in paraneoplastic membranous nephropathy, both t H 1 and t H 2 cytokines may be activated by tumor antigens or other stimulants, resulting in the unique pattern of igG subtype and increased numbers of inflammatory cells. more studies are needed to confirm this hypothesis, and more importantly, to establish whether increased numbers of inflamma tory cells and igG1 and igG2 staining are diagnostic for paraneoplastic membranous nephropathy and justify an intensive investigation for malignancy.
Minimal change disease mCD has been reported in association with lung, colon, and renal cancers (Figure 1 ). similar to membranous nephropathy, ablation of the tumor frequently results in remission of mCD; therefore, factors produced by cancer cells might contribute to the pathogenesis of paraneoplastic mCD. vascular endothelial growth factor (veGF) is one potential candidate because of its ability to increase glomerular permeability. taniguchi et al. 14 reported a patient with rectal adenocarcinoma associated with mCD in whom levels of veGF were elevated. after tumor resection, proteinuria disappeared and veGF levels decreased to normal. the role of veGF in the pathogenesis of mCD and FsGs is further supported by the findings that overexpression of veGF in podocytes induces collapsing FsGs in experimental animal models 15 and that serum veGF levels are elevated in children with nephrotic syndrome. 16 whether mCD is indeed a consequence of veGF overexpression in cancer cells remains to be determined.
Membranoproliferative glomerulonephritis membranoproliferative glomerulonephritis has been reported in association with solid tumors, such as lung, renal and gastric cancers, albeit rarely ( Figure 1) . 3 in these patients, tests for hepatitis C virus (HCv) and cryoglobulin were negative, [17] [18] [19] which led one group of researchers to propose that paraneoplastic membranoproliferative glomerulonephritis is an immune-complex disease that is induced by the combination of tumor antigen formation and the inability of the host to effectively clear antigens. 17 tumor removal has been shown to induce remission of membranoproliferative glomerulonephritis in some cases. 17, 20 interestingly, one case of membranoproliferative glomerulonephritis developed after surgical removal of a bronchial carcinoid tumor, but responded to prednisone therapy. 18 Prednisone was also effective for paraneoplastic membrano proliferative glomerulonephritis without ablation of tumors in two reported cases with metastatic prostate cancers. 19 therefore, the primary treatment goal for membranoproliferative glomerulonephritis associated with solid tumors is tumor ablation. in instances in which this goal is not possible, a trial of prednisone treatment to control nephrotic syndrome seems reasonable.
rapidly progressive glomerulonephritis rPGn has been reported in association with malignancies, in particular renal cell carcinoma, gastric, and lung cancers. in 1984, Biava et al. 21 reported seven cases of rPGn associated with a coexisting non renal malignancy (six carcinomas and one lymphoma). although this study was reported before the discovery of anti neutrophil cytoplasmic antibodies (anCas), an assessment of renal pathology revealed pauci-immune crescentic glomerulonephritis, consistent with vasculitis. Patients with anCaassociated vasculitis have a higher risk of malignancy than the general population; 22, 23 however, many of these malignancies may relate to the immunosuppressive therapy given for treatment of vasculitis. 24 the association of anCa-associated vasculitis with solid tumors has been sporadically reported. 22, 23, [25] [26] [27] [28] these reports demonstrate that anCa-associated vasculitis can occur concurrently with cancer, but cancers are frequently diagnosed after the initial diagnosis of vasculitis. the pathogenetic mechanisms by which neoplasms lead to the development of anCa-associated vasculitis and rPGn are largely unknown. moreover, only a few case reports describe the response of para neoplastic rPGn to treatment. administration of prednisone and cyclo phosphamide-agents that are typically given for anCa-associated vasculitis-to patients who had undergone tumor removal resulted in partial or complete remission of vasculitis in most patients. 27 whether vasculitis responds to tumor ablation alone has not been tested; however, two patients who had untreatable cancers achieved remission of vasculitis in response to immunosuppressive therapy. 25, 26 in patients in whom tumor removal will be performed, paraneoplastic rPGn can be treated with steroid and cyclophosphamide immediately, to prevent irreversible damage of the kidney. revieWs igA nephropathy the association between iga nephropathy and solid tumors of the respiratory tract, buccal mucosa and nasopharynx was first reported by mustonen et al. 29 in 1984. subsequent reports of paraneoplastic iga nephropathy mainly described patients with renal cell carcinoma ( Figure 1) . 7, 30 the paraneoplastic nature of iga nephropathy is supported by the finding that iga nephropathy resolved after tumor removal and evidence of iga staining within the renal cell carcinoma. 7 interestingly, a diagnosis of renal cell carcinoma was made in two patients because of the rapid growth of renal lesions in response to corticosteroid therapy for iga nephropathy. 30 tumor ablation seems to be the treatment of choice for para neoplastic iga nephropathy, whereas corticosteroid therapy may promote tumor growth. Henoch-schönlein purpura (HsP)-a systemic vasculitis that occurs in association with iga nephropathy-has also been reported in association with solid tumors, most commonly lung cancers. 31 information on the treatment of paraneoplastic HsP is limited. 31 Thrombotic microangiopathy thrombotic microangiopathy is a multisystemic dis order that leads to thrombocytopenia, microangiopathic hemolytic anemia and ischemic manifestations owing to platelet agglutination. Damage to the central nervous system and kidney can also manifest. strictly speaking, thrombotic microangiopathy is not considered to be a form of glomerulonephritis; however, discussion of thrombotic microangiopathy is included in this review because the renal manifestations of thrombotic micro angiopathy, such as hematuria and proteinuria, are similar to those that occur with glomerulonephritis. thrombotic microangiopathy broadly includes thrombocytopenic thrombotic purpura (ttP) and hemolytic uremic syndrome (Hus); however, the discovery of aDamts13 has led to the classification of thrombotic microangiopathy being better defined. 32 thrombotic microangiopathy has been observed in patients with mucin-producing carcinomas, predominantly gastric, lung and breast cancers. at the time of thrombotic microangiopathy diagnosis, the malignancy can either be widely disseminated or isolated to the bone marrow. 33 Patients with cancerassociated thrombotic microangiopathy do not have severely impaired aDamts13 activity and respond poorly to plasma exchange therapy. 34 the pathogenesis of cancer-associated thrombotic microangiopathy therefore clearly differs from ttP, in which aDamts13 activity is generally below 5% of normal and response rate to plasma exchange therapy is high. 32 Cancer-associated thrombotic microangiopathy is most likely caused by microvascular tumor emboli and as such, thrombotic microangiopathy is not strictly speaking a paraneoplastic syndrome because it is directly related to tumor metastasis. the striking differ ences between cancer-associated thrombotic micro angiopathy and ttP were illustrated by Francis et al. 35 who examined a series of 10 patients with 'cancer-associated thrombotic microangiopathy' from the oklahoma ttP/Hus registry. these patients fulfilled the clinical criteria for ttP and received plasma exchange therapy, but unfortunately died soon after the initial diagnosis of ttP. malignancy was diagnosed by bone marrow biopsy in six patients and on autopsy in two. overall, cancerassociated thrombotic microangiopathy seems to carry a poor prog nosis. Diagnosis is frequently difficult and may require a bone marrow biopsy. the lack of response to plasma exchange therapy could be an important hint for investigating malignancy as a cause of thrombotic microangiopathy. Plasma exchange therapy is not recommended once a diagnosis of cancer-associated thrombotic micro angiopathy has been made. 35 
Hematological malignancies
Hematological malignancies are heterogeneous diseases of different cell lineages. in this review, lymphoid, myeloid, and thymus malignancies are discussed separately because the patterns and pathogenetic mechanisms of these neoplasms are different. of note, although thymoma-associated paraneoplastic glomerulonephritis is extremely rare, it serves as a unique disease model for investigating t-cell dysregulation as a potential pathogenetic mechanism for glomerular lesions and deserves separate discussion.
lymphoid malignancies Paraneoplastic glomerulonephritides are well known to occur in association with chronic lymphoid neoplasms, but rarely occur in patients with acute lymphocytic leukemia. 36 in addition to being associated with Hodgkin lymphoma, non-Hodgkin lymphoma and chronic lympho cytic leukemia, 36,37 specific types of glomerulonephritis have been reported in association with rare lymphoid malignancies, such as cutaneous t-cell lymphoma (which includes mycosis fungoides and the leukemic variant, sézary syndrome), 38, 39 and hairy cell leukemia (a chronic mature B-cell lymphoproliferative disease, in which B cells possess abundant cytoplasms with microfilamentous 'hairy' projections). 40, 41 mCD is the most common paraneoplastic glomerulonephritis associated with Hodgkin lymphoma, followed by FsGs, whereas membranoproliferative glomerulonephritis and membranous nephropathy are more commonly associated with chronic lymphocytic leukemia, hairy cell leukemia, and non-Hodgkin lymphoma (Figure 2) . iga nephropathy has only been reported in association with cutaneous t-cell lymphoma. these patterns of disease are interesting from an immunological viewpoint because Hodgkin lymphoma is predominantly a disease of the t-cell lineage, whereas chronic lympho cytic leukemia, hairy cell leukemia and most non-Hodgkin lymphomas are B-cell-lineage diseases.
MCD and FSGS
mCD occurs in about 1% of patients with Hodgkin lymphoma and the occurrence of FsGs is about onetenth that of mCD. 36, 37 audard et al. 37 retrospectively evaluated a cohort of 21 adult patients with mCD and classic Hodgkin lymphoma. mCD was diagnosed in close proximity to Hodgkin lymphoma or its relapse revieWs in about half these patients. Both Hodgkin lymphoma and mCD responded to chemotherapy. Hodgkin lymphoma was diagnosed many months after mCD in five patients. mCD in these five patients was resistant to steroid and ciclosporin therapy, and only responded to chemotherapy. similarly, excellent responses to chemotherapy were observed in patients with Hodgkinlymphoma-associated FsGs. 36 a poor response of mCD to steroid or ciclosporin therapy therefore seems to be indicative of occult Hodgkin lymphoma.
a further clinical observation made by audard and colleagues 37 was that 71% of patients with Hodgkin lymphoma and mCD had systemic symptoms (that is, fever, weight loss, and night sweats), and 90% had positive laboratory parameters for inflammatory syndrome (as assessed by C-reactive protein level, sedimentation rate, and fibrinogen level). 37 increased cytokine levels, particularly levels of t H 2 cytokines, could be responsible for this inflammatory response since Hodgkin lymphoma is associated with an expansion of t cells polarized towards a t H 2-like phenotype. 42 Furthermore, il-13, a t H 2-type cytokine, and its receptor are constitutively expressed in reed-sternberg cells in patients with Hodgkin lymphoma. 43 a 2007 study demonstrated that over expression of il-13 in rats induces a mCD-like nephropathy character ized by proteinuria, hypoalbuminemia, hypercholesterolemia, and fusion of podocyte foot processes. 44 Further studies are needed to verify whether il-13 is the plasma vascular permeability factor that causes mCD and/or FsGs in patients with Hodgkin lymphoma.
Membranoproliferative glomerulonephritis the incidence of nephrotic syndrome in patients with chronic lymphocytic leukemia is less than 1%, with membrano proliferative glomerulonephritis being the most common pathology. 45 membranoproliferative glomerulonephritis in the setting of chronic lymphocytic leukemia, hairy cell leukemia and B-cell non-Hodgkin lymphoma might be caused by monoclonal immunoglobulin, which is secreted by B-cell clones. in some cases, membranoproliferative glomerulonephritis is associ ated with mixed cryoglobulinemia, mainly comprising types i and ii, which involves a monoclonal immunoglobulin. 46 in the past 2 decades, HCv infection has been implicated in the development of B-cell non-Hodgkin lymphoma. in a series that included 16 patients with HCv infection complicated by type ii mixed cryoglobulinemia and membranoproliferative glomerulonephritis, examination of bone marrow biopsy samples revealed low-grade B-cell non-Hodgkin lymphoma in 68% of patients. 47 the high incidence of subclinical lymphoma suggests that type ii mixed cryoglobulinemia is a precancer condition and that the expansion of clonal B cells may eventually progress to B-cell lymphoma. this sequence of events may also occur in patients with non-HCv mixed cryoglobulinemia. in a series of 20 patients with nonHCv-associated type ii mixed cryoglobulinemia and membranoproliferative glomerulonephritis, four patients developed B-cell lymphoma; two of these had a relapse of membranoproliferative glomerulonephritis. 48 the assumption that membranoproliferative glomerulo nephritis with type ii mixed cryo globulinemia may represent a paraneoplastic glomerulonephritis owing to occult B-cell lymphoma has considerable clinical implications. the response rate of HCv-associated type ii mixed cryoglobulinemia to combined treatment with interferon and ribavirin is about 60%. 49 Patients who failed to respond to interferon and ribavirin, however, responded well to rituximab, an anti-B-cell (CD20) monoclonal antibody, which is used to treat B-cell malignancies. 50 it is possible that patients who responded to rituximab had paraneoplastic membranoproliferative glomerulonephritis associated with subclinical B-cell lymphoma, which was induced by HCv infection.
Membranous nephropathy membranous nephropathy is less common than membrano proliferative glomerulonephritis in relation to lymphoid malignancies. in one series of glomerulo nephritis associated with chronic lymphocytic leukemia and nonHodgkin lymphoma, the ratio of membrano proliferative glomerulonephritis to membranous nephro pathy was 8:1. 51 Features atypical of membranous nephro pathy, including segmental mesangial prolifera tion, subepithelial deposits of fibrillary material, and mono clonal igG kappa light chain deposits, have been reported in disease associated with chronic lymphocytic leukemia and non-Hodgkin lymphoma. 51, 52 some of these findings suggest that similar to membrano proliferative glomerulo nephritis, monoclonal proteins produced revieWs by B cells may be involved in the pathogenesis of para neoplastic membran ous nephro pathy. of note, paraneoplastic membran ous nephropathy frequently responds to treatment of the underlying malignancy.
IgA nephropathy iga nephropathy has been reported in patients with cutaneous t-cell lymphoma, and seems to have a relatively stable clinical course. 39 as in patients with Hodgkin lymphoma, t H 2 polarization has been observed in patients with cutaneous t-cell lymphoma. 53 whether skin involvement of the malignancy has any role in the pathogenesis of iga nephropathy is unclear.
Myeloid malignancies
Chronic myeloid malignancies are a highly heterogeneous group of disorders and can occur in association with a variety of glomerulonephritides. However, paraneoplastic glomerulonephritides have been reported infrequently in patients with myeloid neoplasms. in particular, acute myelogenous leukemia, like acute lymphocytic leukemia, has been rarely reported in association with glomerulonephritides ( Figure 3) . [54] [55] [56] elucidation of the molecular pathogenetic mechanisms of several myeloid neoplasms has led to the reclassification of chronic myeloid neoplasms into three categories: myeloproliferative neoplasms, myelodysplastic syndromes and myelodysplastic-myeloproliferative disorders (table 1) . 57, 58 among the myeloproliferative neoplasms, polycythemia vera, essential thrombocythemia and primary myelofibrosis are associated with FsGs and mesangial proliferative glomerulonephritis.
59-61 the prevalence of glomerulonephritis in patients with polycythemia vera, essential thrombocythemia and primary myelo fibrosis is about 3.6%. 60 the val617Phe mutation in JaK2, which causes abnormal cell proliferation, is present in more than 90% of patients with polycythemia vera and in nearly half of those with essential thrombocythemia or primary myelofibrosis. 57 Patients with this mutation have abnormal megakaryocytes, in terms of both number and function. High platelet counts have been proposed as a risk factor for FsGs. Plasma and urine levels of plateletderived growth factor (PDGF) are elevated in patients with myeloproliferative neoplasms 62 and PDGF has been shown to enhance mesangial proliferation and fibrosis. 63 indeed, in one case of FsGs associated with essential thrombocythemia, nephrotic syndrome occurred after a sudden rise in platelet count following a splenectomy. 64 interestingly, although thrombocytosis also occurs in chronic myelogenous leukemia, FsGs has not been reported to be associated with chronic myelo genous leukemia, and plasma PDGF levels in patients with chronic myelogenous leukemia were normal. 62 treatment with myelosuppressive agents or regular phlebotomies for myeloproliferative neoplasms has achieved partial remission of FsGs in some cases. 60, 65, 66 Chronic myelogenous leukemia is the most common myeloproliferative neoplasm, but is rarely associated with glomerulonephritis. all individuals that have chronic myelogenous leukemia carry the Philadelphia chromosome, which encodes the BCr-aBl1 fusion protein that dysregulates tyrosine kinase function. 57 Chronic myelo genous leukemia has an indolent clinical course, which has led to the suggestion that glomerulonephritis might occur independently of the malignancy. [54] [55] [56] [59] [60] [61] [64] [65] [66] [67] [68] [69] [70] [71] [72] [74] [75] [76] [77] 79, [102] [103] [104] [105] [106] [107] [108] [109] [110] [111] [112] [113] [114] and are presented as numbers of specific types of paraneoplastic glomerulonephritides associated with different myeloid malignancies. Abbreviations: AML, acute myeloid leukemia; CML, chronic myelogenous leukemia; CMML, chronic myelomonocytic leukemia; ET, essential thrombocythemia; Fib GN, fibrillary glomerulonephritis; FSGS, focal segmental glomerulosclerosis; igAN, igA nephropathy; MCD, minimal change disease; MDS, myelodysplastic syndrome; MesPGN, mesangial proliferative glomerulonephritis; MN, membranous nephropathy; MPGN, membranoproliferative glomerulonephritis; PMF, primary myelofibrosis; Pv, polycythemia vera; RPGN, rapidly progressive glomerulonephritis. revieWs in support of this theory, immunosuppressive therapy was effective in two cases of mCD and one of rPGn without any effect on the chronic myelogenous leukemia. [67] [68] [69] on the other hand, one case of membranoproliferative glomerulo nephritis associated with chronic myelogenous leukemia reportedly responded to the tyrosine kinase inhibitor imatinib, suggesting that chronic myelogenous leukemia may cause or exacerbate membranoproliferative glomerulonephritis. 70 the clinical presentations of myelodysplastic syndrome range from indolent conditions with a nearnormal life expectancy to forms approaching the severity of acute myelogenous leukemia. 58 the prevalence of para neoplastic glomerulonephritis in patients with myelo dysplastic syndrome and chronic myelomonocytic leukemia (Cmml)-a myelodysplasticmyelo proliferative dis order-is 2% and 27%, respectively, as reported in a small series of 114 patients with myelodysplastic syndrome and 11 patients with Cmml. 71 myelodysplastic syndrome is associated with autoimmunity and approximately 10% of patients with myelodysplastic syndrome have clinical autoimmune disorders. 72 the transformation of normal bone marrow stem cells into dysplastic cells has been suggested to induce an autoimmune t-cell response with the bone marrow as the target organ. this autoimmune attack results in a chronic overproduction of cytokines, such as tnF. 73 these cytokines may have an important role in the development of paraneoplastic glomerulonephritis associated with myelodysplastic syndrome. a variety of glomerulonephritides have been reported to be associated with myelodysplastic syndrome (Figure 3) , and in general, their response to immunosuppressive treatment is good. [74] [75] [76] only one case of membran ous nephropathy and one of membranoproliferative glomerulonephritis have been reported in association with Cmml, possibly because kidney biopsy is frequently contraindicated in these patients. 77 monocytes may be involved in pathogenesis of paraneoplastic glomerulonephritis since monocyte counts are higher in patients with nephrotic range proteinuria than in those without. 71 of note, severe monocytosis causes marked lysozymuria, which may present as nephrotic range proteinuria. 78 this pseudonephrotic syndrome should be excluded before a diagnosis of paraneoplastic glomerulonephritis is made. Chemotherapy effectively ameliorated paraneoplastic glomerulonephritis in three patients, 71, 77 and a 2008 case report demonstrated mycophenolate mofetil treatment to be effective for Cmml-associated membranous nephropathy. 79 Thymoma thymoma is a rare malignancy that is unique because of its association with a variety of autoimmune diseases, including myasthenia gravis, systemic lupus erythematosus, pure red cell aplasia, and pemphigus vulgaris. this association implies that severe t-cell dysregulation occurs in patients with thymoma-a feature that may be implicated in the pathogenesis of thymoma-associated paraneoplastic glomerulonephritis. the prevalence of paraneoplastic glomerular diseases in patients with thymoma is about 2%, higher than that for Hodgkin lymphoma. mCD is the most common para neoplastic glomerulonephritis associated with thymoma, followed by membranous nephropathy, FsGs, rPGn, and lupus nephritis (Figure 4 ). in 2005, Karras et al. 80 reported the largest series of paraneoplastic glomerulonephritis associ ated with thymoma. interestingly, they observed that thymoma-associated membranous nephro pathy revieWs seemed to have a distinct clinical presentation from that of thymoma-associated mCD. Histologically, thymoma can be divided into epithelial-predominant or lymphocyte-predominant tumors. membranous nephropathy tends to be associated with epithelial-predominant thymoma, is always diagnosed with either a newly diagnosed or recurrent thymoma, and typically resolves after tumor ablation. 80 mCD tends to be associated with lymphocyte-predominant thymoma, is frequently diagnosed after tumor removal, and responds relatively well to steroid therapy (with a combined complete and partial remission rate of 60%). thymoma-associated membranous nephropathy seems to have a similar pathogenetic mechanism to that of solid tumor-associated membranous nephropathy, whereas thymoma-associated mCD could be associated with persistent t-cell dysfunction after thymoma removal. 80 over the past two decades, the Buffalo/mna rat has been used as an experimental model of combined thymoma, myasthenia and glomerulopathy. thymoma in this model is characterized by primary hyperplasia of cortical epithelial cells and a large number of proliferating lymphocytes, which have a normal distribution of CD5 + ,
CD4
+ and CD8 + t cells. 81 nephrotic syndrome appears at 1 month of age and renal pathology initially shows an mCD-like glomerular disease followed by the late develop ment of FsGs. thymectomy either in infancy 82 or adulthood 83 does not prevent or attenuate the nephrotic syndrome. renal macrophage activation, t-cell infiltration, and t H 2 polarization precede the develop ment of nephrotic syndrome in this model. 83 these findings are consistent with the hypothesis proposed by shalhoub over 35 years ago that mCD is caused by t-cell dysfunction. 84 Corticosteroids or other immuno suppressive drugs such as cyclophosphamide and ciclosporin are, however, ineffective for treating this disease. 83 in 2009, le Berre et al. found that induction of t-regulatory (t reG ) cells attenuated the nephrotic syndrome in Buffalo/mna rats. induction of t reG cells also reduced renal macrophage and t-cell infiltration and suppressed renal messenger (m)rna expression of the t H 2-type cyto kines il-10 and il-13 but did not affect mrna levels of the t H 1-type cytokine tnF. 85 these studies confirm the importance of t H 2 polarization in thymoma-associated nephrotic syndrome, and suggest that induction of t reG cells could be a new potential therapeutic strategy for thymoma-associated mCD and FsGs.
Management the most difficult issue in the management of paraneoplastic glomerulonephritis is the clinical recognition of this syndrome. the consequence of delayed diagnosis could be serious because patients may be subjected to potentially harmful treatment. in patients who present with glomerulonephritis and a pre-existing neoplasm, it is important to rule out glomerular lesions induced by cancer treatment. Bone marrow transplanta tion is known to cause membranous nephropathy via graft-versus-host disease. 86 a variety of glomerular diseases are induced by anticancer agents (table 2) . 87 thrombotic microangiopathy is the most common lesion caused by chemotherapy agents. mitomycin C is associated with a 2-10% risk of thrombotic micro angiopathy; this risk increases considerably for cumulative doses of ≥40 mg/m 2 .
88
newer agents known to induce thrombotic microangiopathy include gemcitabine and anti-veGF agents. Gemcitabine-induced thrombotic micro angiopathy is dose-related and usually reversible if diagnosed early. similar to other causes of drug-induced thrombotic microangiopathy, plasma exchange therapy is not helpful in this setting. 89 thrombotic microangiopathy induced by anti-veGF agents is mainly restricted to renal presentation, that is, characterized by proteinuria, hypertension and acute kidney injury. microangiopathic hemolysis and thrombocytopenia are rarely reported. 90 lastly, high dose pamidronic acid 91 and interferon α 92 have been reported to cause collapsing FsGs and FsGs, respectively. the recognition of paraneoplastic glomerulo nephritis before the detection of malignancy requires a high index of suspicion. routine age-appropriate screening for malignancy should be performed in patients with glomerulonephritis, including fecal occult blood testing and colonoscopy in patients over 50 years of age (or if indicated for other reasons), mammography in women over 40 years of age, and prostate specific antigen testing in men over 50 years of age. Patients with a history of smoking should be assessed by chest radiography or possibly chest Ct to exclude lung cancer. investigation for Hodgkin lymphoma is warranted for patients with mCD, particularly in those who have systemic symptoms or who are resistant to traditional mCD treatment. revieWs initial studies for patients with membranoproliferative glomerulo nephritis should include assessment of HCv status and testing for cryoglobulins and monoclonal immunoglobulins. Bone marrow biopsy is indicated if any hint of occult lymphoma or leukemia is present. a multidisciplinary approach involving nephrologists, oncologists and other care givers is necessary for treating both malignancy and paraneoplastic glomerulo nephritis. symptomatic treatment for nephrotic syndrome in paraneoplastic glomerulonephritis is the same as in non cancer patients. specific treatment for cancer-associated glomerular lesions (table 3) is often different from that used for idiopathic glomerulonephritis. these recommendations are mainly based on case series and reports as reviewed in previous sections. after successful treatment, long-term follow-up with renal function tests, urinalysis, and spot urine protein:creatinine ratio measure ment is important for patients with para neoplastic glomerulo nephritis. For specific glomerulo nephritides, serology testing, for example, for cryoglobulin, monoclonal immunoglobulin and anCa, should be performed. recurrence of any glomerular lesion should prompt a work up for cancer relapse. likewise, any recurrence of malignancy should alert physicians to look for recurrence of paraneoplastic glomerulonephritis.
Conclusions
Paraneoplastic glomerulonephritis, a rare secondary cause of glomerulonephritis and a complication of cancer, remains a challenge to both nephrologists and oncologists. altered immune responses seem to have a role in the pathogenesis of paraneoplastic glomerulo nephritis. this notion is supported by studies in Buffalo/mna rats, in which t H 2 polarization induces thymoma-associated mCD and FsGs. 83, 85 recognition of paraneoplastic glomerulo nephritis and the subsequent detection of an undiagnosed malignancy could be life-saving. the treatment of paraneoplastic glomerulonephritis is targeted at the cause-the neoplasm-and requires a multidisciplinary approach to monitor both the cancer and the glomerular lesions. studies to identify diagnostic biomarkers of paraneoplastic glomerulonephritis in blood, urine, or kidney biopsy samples by use of proteomic or other approaches are critically needed to facilitate the early diagnosis of this disease.
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